All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Did you miss ASH 2018? The GvHD Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA, USA, and has developed a downloadable resource, which provides information on the practice changing abstracts across graft-versus-host disease (GvHD).
Our selection of ASH abstracts include comments from The GvHD Hub Steering Committee members on promising new therapeutic and prophylactic options; ruxolitinib for steroid refractory GvHD, KD025 for chronic GvHD, and vedolizumab for GvHD prophylaxis. Hear from the experts on the role of the microbiome, genetic risk factors and potential biomarkers in GvHD.
ASH 2018 | Practice changing abstracts in graft-versus-host disease
If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the GvHD Hub resource below:Download Here
ASH 2019 | Practice-changing abstracts in graft-versus-host disease
The GvHD Hub Steering Committee shared the updated top abstracts from ASH 2019 that they believe could have the greatest impact on clinical practice, in preparation for ASH 2020.
EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?
Robert Zeiser from the University Medical Center Freiburg, Freiburg, DE, discusses the recommendations for the treatment of acute...
Subscribe to get the best content related to GvHD delivered to your inbox